No information is available on the clinical use of trastuzumab during breastfeeding. Because trastuzumab is a large protein molecule with a molecular weight of 145,531 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. Until more data become available, trastuzumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.[1] The manufacturer recommends that breastfeeding be discontinued during trastuzumab therapy and for 7 months after the last dose.
关于曲妥珠单抗在母乳喂养期间的临床应用尚无可用信息。由于曲妥珠单抗是一种分子量为145,531道尔顿的大分子蛋白质，乳汁中的含量可能非常低。它也可能在婴儿胃肠道中被部分破坏，婴儿的吸收可能极少。在获得更多数据之前，母乳喂养期间应谨慎使用曲妥珠单抗，尤其是在哺育新生儿或早产儿期间。[1]制造商建议在曲妥珠单抗治疗期间及最后一剂后7个月内停止母乳喂养。
